Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication

Stock Information for KULR Technology Group Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About KULR Technology Group Inc.

Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
Voyager Reports First Quarter 2025 Financial and Operating Results
Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD(TM) 2025
Bragar Eagel & Squire, P.C. Is Investigating Dave, Red Cat, Perpetua, and Voyager and Encourages Investors to Contact the Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.